Get the Stockscreener App
120.79
0.44%
0.53
After Hours:
120.70
-0.09
-0.07%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $120.79, with a volume of 14.37M.
It is up +0.44% in the last 24 hours and up +6.75% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$120.26
Open:
$120.935
24h Volume:
14.37M
Relative Volume:
1.50
Market Cap:
$298.33B
Revenue:
$65.51B
Net Income/Loss:
$8.93B
P/E Ratio:
33.99
EPS:
3.5532
Net Cash Flow:
$14.12B
1W Performance:
+1.74%
1M Performance:
+6.75%
6M Performance:
+21.13%
1Y Performance:
+55.62%
1-Day Range:
$120.36
$123.46
1-Week Range:
$114.36
$123.46
52-Week Range:
$76.66
$125.14
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck & Co., Inc. $MRK Stake Cut by ING Groep NV - MarketBeat
Los Angeles Capital Management LLC Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Is Merck & Co. stock outperforming the S&P 500? - MSN
Dearborn Partners LLC Decreases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Vestcor Inc Sells 22,707 Shares of Merck & Co., Inc. $MRK - MarketBeat
Westfield Capital Management Co. LP Invests $5.64 Million in Merck & Co., Inc. $MRK - MarketBeat
PBU The Pension Fund of Early Childhood & Youth Educators Takes Position in Merck & Co., Inc. $MRK - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 127,100 Shares of Merck & Co., Inc. $MRK - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Grows Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Rating Increased to Buy at Wall Street Zen - MarketBeat
Is Merck & Co. (MRK) One of the Best Cheap Stocks to Buy for Beginners? - Insider Monkey
Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise (NYSE:MRK) - Seeking Alpha
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Vise Technologies Inc. Has $11.65 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Prudential PLC Cuts Stake in Merck & Co., Inc. $MRK - MarketBeat
J.W. Cole Advisors Inc. Sells 16,943 Shares of Merck & Co., Inc. $MRK - MarketBeat
Daiwa Securities Group Inc. Sells 72,786 Shares of Merck & Co., Inc. $MRK - MarketBeat
MRK Stock Quote Price and Forecast - CNN
Merck & Co., Inc. $MRK Shares Acquired by Arrowpoint Investment Partners Singapore Pte. Ltd. - MarketBeat
A Look at Merck & Co Inc (MRK) After 4.8% Gain -- GF Value $118.24 vs Price $120.26 - GuruFocus
Merck & Co Inc Stock (MRK) Moved Up by 3.33% on Jun 4: What Signal Does It Send? - TradingKey
TD Asset Management Inc Grows Position in Merck & Co., Inc. $MRK - MarketBeat
Cibc World Market Inc. Purchases 320,143 Shares of Merck & Co., Inc. $MRK - MarketBeat
Westpac Banking Corp Sells 63,983 Shares of Merck & Co., Inc. $MRK - MarketBeat
Marble Wealth LLC Invests $1.13 Million in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
CIBC Asset Management Inc Boosts Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Bank of New York Mellon Corp Reduces Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (MRK) Presents at American Society of Clinical Oncology (ASCO) Annual Meeting 2026Slideshow - Seeking Alpha
Merck & Co. Inc. stock (US58933Y1055): Shares ease as investors eye upcoming healthcare conference a - AD HOC NEWS
Merck & Co. (MRK) Announces Quarterly Dividend - Yahoo Finance
Is Merck & Co., Inc. (MRK) Expanding KEYTRUDA’s Reach With New EU Approval Momentum? - Insider Monkey
Global Sustainability Awards 2026 Opens Final Call for Entries as Industry Leaders Prepare to Celebrate Sustainability Excellence - GlobeNewswire Inc.
Natixis Advisors LLC Buys 217,330 Shares of Merck & Co., Inc. $MRK - MarketBeat
Pincus Capital Management LP Acquires Shares of 42,804 Merck & Co., Inc. $MRK - MarketBeat
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - BioSpace
Merck & Co., Inc. $MRK Shares Bought by One Capital Management LLC - MarketBeat
BNP Paribas Sells 17,542 Shares of Merck & Co., Inc. $MRK - MarketBeat
What Keeps Merck At The Center Of Global Healthcare Innovation? - Kalkine Media
Merck & Co., Inc. stock (US58933Y1055): shares steady on NYSE as investors digest recent news flow - AD HOC NEWS
Merck exec says company is discussing use of COVID antiviral drug in Ebola response - Reuters
Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ” - Yahoo Finance
Merck & Co Inc Stock (MRK) Moved Down by 3.19% on Jun 1: A Full Analysis - TradingKey
Merck (MRK) Strengthens Capital Structure With Notes Offering - Yahoo Finance
Merck & Co. Inc. stock (US58933Y1055): Q3 2026 dividend confirmed as NYSE trading holds steady - AD HOC NEWS
Hillsdale Investment Management Inc. Trims Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Company, Inc. (MRK) Stock Analysis: Strong Buy Ratings and Potential Upside for Investors - DirectorsTalk Interviews
Easterly Investment Partners LLC Cuts Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Founders Financial Securities LLC Sells 16,726 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. (MRK) Announces FDA’s Grant of Breakthrough Therapy Designation for Calderasib - Insider Monkey
Merck’s (MRK) Deep Drug Pipeline Could Power its Next Chapter - Yahoo Finance
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merck Co Inc Stock (MRK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Maraldo David R. | EVP & Pres. MMD |
May 02 '26 |
Option Exercise |
112.16 |
552 |
61,912 |
18,371 |
| Guindo Chirfi | EVP, Access, Policy & Comms |
Apr 29 '26 |
Option Exercise |
110.03 |
1,967 |
216,429 |
62,582 |
| Chattopadhyay Sanat | Exe V-P & Pres. MMD |
Apr 29 '26 |
Option Exercise |
110.03 |
2,597 |
285,748 |
16,477 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Apr 29 '26 |
Option Exercise |
110.03 |
2,518 |
277,056 |
162,778 |
| Williams David Michael | EVP,Chief Info&Digital Officer |
Apr 29 '26 |
Option Exercise |
110.03 |
1,377 |
151,511 |
32,395 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 29 '26 |
Option Exercise |
110.03 |
944 |
103,868 |
9,156 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 30 '26 |
Option Exercise |
110.95 |
464 |
51,481 |
9,296 |
| Li Dean Y | Executive VP & President, MRL |
Apr 29 '26 |
Option Exercise |
110.03 |
4,722 |
519,562 |
96,757 |
| Zachary Jennifer | EVP, General Counsel |
Apr 29 '26 |
Option Exercise |
110.03 |
2,951 |
324,699 |
72,351 |
| Larson Betty D | EVP, Chief HR Officer |
Apr 30 '26 |
Option Exercise |
110.95 |
11,350 |
1,259,282 |
18,917 |
2.28%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):